Online GLP-1 Telehealth Providers
A practical, vendor-neutral framework for comparing online GLP-1 telehealth providers on licensing, medical oversight, pharmacy disclosure, and pricing transparency.
What is an online GLP-1 telehealth provider?
An online GLP-1 telehealth provider is a platform that connects patients with state-licensed clinicians who can evaluate eligibility for GLP-1 medications (such as semaglutide or tirzepatide) and, when clinically appropriate, prescribe them for fulfillment by a licensed pharmacy. A trustworthy provider verifies medical eligibility, follows state telehealth rules, discloses how medication is sourced, and is clear about total monthly cost.
Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
How to evaluate GLP-1 telehealth programs
Strong programs share a few traits: licensed clinical oversight, transparent pricing, named pharmacy fulfillment, and accurate language about compounded medications. Weigh these consistently rather than reacting to the lowest advertised price.
Pricing transparency
Look past the “starting at” figure. Because GLP-1 medications are titrated over several weeks, the maintenance-dose price is what determines long-term cost. For an independent month-to-month view across programs, see the GLP-1 Price Index.
Provider licensing
Confirm the provider uses clinicians licensed in your state and that a medical review precedes any prescription. State telehealth requirements vary.
Pharmacy transparency
A credible provider names its compounding pharmacy and its category (503A or 503B). See our 503A vs 503B explainer and pharmacy transparency guide.
Safety red flags
- No medical review before prescribing
- No clarity on state licensure
- No named pharmacy
- Claims that compounded medication is “FDA-approved”
- Hidden subscription or dose-based fees
See the full telehealth red flags list.
Mean weight loss in pivotal GLP-1 trials
| Medication | Trial (year) | Mean weight loss |
|---|---|---|
| Tirzepatide 15 mg | SURMOUNT-1 (2022) | 20.9% |
| Tirzepatide | SURMOUNT-5 (2025) | 20.2% |
| Semaglutide 2.4 mg | STEP 1 (2021) | 14.9% |
| Semaglutide 2.4 mg | SURMOUNT-5 (2025) | 13.7% |
| Oral semaglutide 25 mg | OASIS-4 (2025) | 13.6% |
| Oral orforglipron 36 mg | ATTAIN-1 (2025) | 12.4% |
Data shown in the chart above. Compounded versions are not the FDA-approved products studied in these trials.
Frequently asked questions
Are online GLP-1 telehealth providers legitimate?
Many are, when they use state-licensed clinicians, require a medical review, disclose pharmacy sourcing, and price transparently. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
How much do online GLP-1 programs cost?
It varies by pricing model and dose policy. Compare maintenance-dose, all-in monthly cost across programs using an independent price index.
Is compounded semaglutide the same as Wegovy?
No. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
Sources
- U.S. FDA — Medications containing semaglutide and tirzepatide (fda.gov).
- U.S. Food & Drug Administration — Compounding and the FDA (fda.gov).
- Federation of State Medical Boards — Telemedicine policy resources (fsmb.org).